Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US

por Watson, Tina R., Gao, Xin, Reynolds, Kerry L., Kong, Chung Yin
Publicado 2020

Esophageal cancer treatment costs by phase of care and treatment modality, 2000‐2013

por Tramontano, Angela C., Chen, Yufan, Watson, Tina R., Eckel, Andrew, Hur, Chin, Kong, Chung Yin
Publicado 2019

Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014

por Tramontano, Angela C., Chen, Yufan, Watson, Tina R., Eckel, Andrew, Hur, Chin, Kong, Chung Yin
Publicado 2020

A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea

por Chen, Yufan, Watson, Tina R., Criss, Steven D., Eckel, Andrew, Palazzo, Lauren, Sheehan, Deirdre F., Kong, Chung Yin
Publicado 2019

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States

por Criss, Steven D., Mooradian, Meghan J., Watson, Tina R., Gainor, Justin F., Reynolds, Kerry L., Kong, Chung Yin
Publicado 2019

Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden

por Criss, Steven D., Palazzo, Lauren, Watson, Tina R., Paquette, Adelle M., Sigel, Keith, Wisnivesky, Juan, Kong, Chung Yin
Publicado 2020

Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000–2013

por Tramontano, Angela C., Chen, Yufan, Watson, Tina R., Eckel, Andrew, Sheehan, Deirdre F., Peters, Mary Linton B., Pandharipande, Pari V., Hur, Chin, Kong, Chung Yin
Publicado 2019